Bank of Montreal
SGTX

Bank of Montreal’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bank of Montreal’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20
Closed -$5K – 5254
2021
Q1 		$5K Buy
+20
New +$7.95K ﹤0.01% 4679

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal's SGTX Position: Q2 2021 in Review

Bank of Montreal sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2021, closing a stake of 20 shares — an estimated $5K sold.

Bank of Montreal first reported a position in SGTX in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 52 funds tracked by Wall St. Rank hold SGTX as of Q2 2021.

  • Bank of Montreal reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 20 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5K.
  • Bank of Montreal first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Bank of Montreal's Sigilon Therapeutics, Inc. Common Stock position peaked at $5K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.